Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Single-Center, Double-Blind, Randomized, Placebo- and Positive Controlled, Double-Dummy, Parallel-Group, Repeated Dose Study With a Nested Cross-Over Comparison Between Moxifloxacin and Placebo to Evaluate the Effect of MD1003 on Cardiac Repolarization in Healthy Adult Subjects

NCT04168723 is registered in ClinicalTrials.gov with MedDay Pharmaceuticals SA as lead sponsor.

NCT NCT04168723
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04168723 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Single-Center, Double-Blind, Randomized, Placebo- and Positive Controlled, Double-Dummy, Parallel-Group, Repeated Dose Study With a Nested Cross-Over Comparison Between Moxifloxacin and Placebo to Evaluate the Effect of MD1003 on Cardiac Repolarization in Healthy Adult Subjects
Lead sponsor
MedDay Pharmaceuticals SA
Phase
Phase 1
Overall status
Unknown status
Start date
November 11, 2019
Completion date
March 5, 2020
Enrollment
64 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers